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visualized with the FLAG-speciÞc mAb M2 and TRITC-
coupled anti-mouse IgG.
11. Plasmid pWS30 (22) was used for inactivation of
cagA. For construction of a cagE2 insertion mutant,
the Hp 26695 chromosomal region (position 574639
to 579587) was ampliÞed by polymerase chain reac-
tion (PCR). The PCR fragment was cloned in pMin1,
mutated by a TnMax transposon derivative as de-
scribed [A. F. Kahrs et al., Gene 167, 53 (1995)], and
used for transformation of strain P12, resulting in the
cagE2 mutant. For construction of P12DcagA, region
579021 Ðto 579905 (cagA-upstream) and 583483 to
584934 (cagA-downstream) of the Hp 26695 ge-
nome were ampliÞed by PCR with 18-nucleotide
ßanking sequences as primers. Fragments were
cloned into pBluescript Xho IÐBam HI sites, separated
by an aphA-3 gene cassette. For complementation,
the cagA gene of 26695 was ampliÞed by PCR and
cloned into the pHel2 vector (Xho IÐBam HI) (15).
The FLAG-tag (Sigma) sequence was fused to the
cagA-downstream primer (59-CGGGATCCTTACTT-
GTCATCGTCGTCCTTGTAGTCAGATTTTTGGAAACC-
ACCTT-3). The 18-nucleotide cagA upstream primer
starts at position 579701 (19). Transformation of Hp
strains was performed as described [R. Haas et al.,
Mol. Microbiol. 8, 753 (1993)].
12. AGS cells (1 3 107) were infected with Hp P12,
incubated for 4 hours (37¡C, 5% CO2), washed 53
with PBS*, and lysed in 500 ml of modiÞed RIPA
buffer [50 mM tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% Na-deoxycholate, 1 mM
PMSF, 1 mM orthovanadate, 1 mM leupeptin,1 mM
pepstatin] (1 hour, 4¡C, gentle shaking). The lysate
was cleared (15,000 rpm, 4¡C, 10 min) and the
protein content adjusted to 3 mg/ml with PBS*.
AK257 (1.7 mg/ml) was added to a total volume of
900 ml; after 1 hour at 4¡C, 40 ml of Protein GÐaga-
rose (Roche) was added and the mixture incubated
for a further 2 hours at 4¡C. After a short centrifu-
gation step (10 s, 6.000g) the supernatant was dis-
carded, and beads were washed four times with 1 ml
of PBS* and suspended in 40 ml of sample solution.
13. The COOH-terminal part of CagA was produced as a
fusion protein with MS2-polymerase and an NH2-
terminal His6-tag by using the Escherichia coli ex-
pression vector pEV40 [ J. Pohlner et al., Gene 130,
121 (1993)]. The fusion protein was expressed and
puriÞed by Ni21Ðnitrilotriacetic acid afÞnity chroma-
tography by standard procedures and used to immu-
nize a rabbit to obtain antiserum AK257. AK175 was
generated by immunization of a rabbit with whole
heat-killed Hp bacteria. Immunoblotting was per-
formed and alkaline phosphatase (AP)Ðcoupled pro-
tein A was used to visualize the antibody bound by
decomposition of nitro blue tetrazolium.
14. After standard infection of AGS cells with Hp strains
(10), cells were washed three times with PBS1, har-
vested with a cell scraper, and treated with PBS*
containing 0.05% (w/v) saponin for 10 min at room
temperature. Cellular debris and bacteria were sepa-
rated from the soluble material by centrifugation (5
min, 6000g) and 0.2-mm pore diameter Þltration of
the supernatant. Pellets were resuspended in 30 ml of
sample solution, and supernatants were precipitated
with chloroform-methanol as described [D. Wessel
and U. I. Flu¬gge, Anal. Biochem. 138, 141 (1984)] and
resuspended in 30 ml of sample solution. Equal
amounts (8 ml) of probes were loaded on 6 or 10%
polyacrylamide gels.
15. D. Heuermann and R. Haas, Mol. Gen. Genet. 257,
519 (1998).
16. Available at www.motif.genome.ad.jp/.
17. The sequence of the P12cagA gene was obtained by
PCR ampliÞcation of the complete gene fragment
from corresponding chromosomal DNA and sequenc-
ing of the cloned genes by primer walking.
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Latent infections with periodic reactivation are a common outcome after acute
infection with many viruses. The latency-associated transcript (LAT ) gene is
required for wild-type reactivation of herpes simplex virus (HSV). However, the
underlying mechanisms remain unclear. In rabbit trigeminal ganglia, extensive
apoptosis occurred with LAT2 virus but not with LAT1 viruses. In addition, a
plasmid expressing LAT blocked apoptosis in cultured cells. Thus, LAT promotes
neuronal survival after HSV-1 infection by reducing apoptosis.
After primary infection of the eye, herpes sim-
plex virus–type 1 (HSV-1) establishes a life-
long latent infection in neurons of the trigemi-
nal ganglia (TGs), with sporadic periods of
reactivation and recurrent disease. Recurrent
ocular HSV (HSV-1 and HSV-2) is a leading
cause of corneal blindness resulting from an
infectious agent. Recurrent genital HSV is a
serious sexually transmitted disease. Latent
HSV infections affect 70 to 90% of adults.
During latency, a single viral gene—the
LAT gene—is abundantly transcribed (1, 2).
LAT is essential for the efficient reactivation of
HSV from latency (3). The primary LAT is 8.3
kb and overlaps the important immediate early
gene ICP0 in an antisense direction. Thus, it
was proposed that LAT may function through
an antisense mechanism (1, 2). However, the
first 1.5 kb of LAT alone is sufficient for wild-
type levels of spontaneous reactivation (4), and
this region does not overlap any known HSV-1
gene. LAT may enhance the establishment or
maintenance of latency (5–8), thereby increas-
ing the pool of latently infected neurons, which
in turn results in increased levels of spontane-
ous and/or induced reactivation (9). Although
studies with one LAT2 mutant have suggested
that a LAT-related function may suppress pro-
ductive-cycle gene expression during acute and
latent infection of mouse trigeminal ganglia
(10, 11), no evidence was presented to show
that LAT caused these effects directly, rather
than through a pleiotropic effect. We recently
reported on a mutant containing a partial dele-
tion of LAT in which neurovirulence was in-
creased (12). This finding suggested that LAT
might protect neurons from being killed by
HSV-1, thereby allowing HSV-1 to establish
latency in more neurons.
To determine whether neurons were being
protected by LAT, we used dLAT2903, a LAT
null mutant derived from the McKrae strain of
HSV-1 (3). This mutant contains a deletion that
includes the LAT promoter and the 59 half of the
stable 2-kb LAT; this deletion (nucleotides
2161 to 11667) results in the absence of LAT
RNAs and does not overlap or interfere with the
ICP0 transcript. Like most LAT mutants,
dLAT2903 has no known deficits other than
being impaired for reactivation from latency.
Thus, dLAT2903 is wild type for replication in
mouse and rabbit eyes, HSV-1–induced eye
disease, replication in TGs, and neurovirulence
(3). However, with dLAT2903, large numbers
of neurons positive for TUNEL (terminal de-
oxynucleotidyl transferase–mediated deoxyuri-
dine triphosphate nick-end labeling) were seen
in rabbit TGs on day 7 after infection (Table 1;
70% of sections, 100% of TGs), whereas in this
experiment TUNEL-positive cells were not de-
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ter for Biotechnology, University of Nebraska, Lincoln,
NE 68583, USA. 3Department of Pathology, University
of Southern California School of Medicine, Los Ange-
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tected in TGs from rabbits infected with wild-
type McKrae. Only small amounts of TUNEL-
positive cells were detected in TGs from
dLAT2903R, a rescued virus in which the de-
leted LAT region was restored. The results for
dLAT2903-infected rabbits were significantly
different from those for the wild type–
infected and dLAT2903R-infected rabbits
[P , 0.001 for sections, P , 0.05 for TGs;
analysis of variance (ANOVA), Tukey compar-
ison test for peak days of apoptosis]. Represen-
tative photomicrographs are shown in Fig. 1.
More rabbits were infected (five rabbits per
group) and killed on day 7 after infection to
study additional aspects of enhanced apoptosis
in rabbits infected with the LAT2 virus (Table
2). Fifty sections per group (five sections from
each of 10 TGs) were examined. Extensive
apoptosis (.25% TUNEL-positive neurons)
was observed in 66% of the sections from
dLAT2903 (LAT2)–infected rabbits, versus
only 4% of the sections from uninfected rab-
bits or rabbits infected with wild-type Mc-
Krae or dLAT2903R (P , 0.001; ANOVA,
Tukey posttest). When all TGs with extensive
apoptosis in at least one section were counted
(Table 2), 90% of TGs from rabbits infected
with dLAT2903 met this criterion, versus
only 10 to 20% of TGs from uninfected
rabbits or rabbits infected with wild-type
McKrae or dLAT2903R (P , 0.01).
When we counted all TG sections with any
amount of apoptosis in neurons, this threshold
was met by 74% of the sections from rabbits
infected with dLAT2903; this was significantly
higher than for TGs from uninfected rabbits or
rabbits infected with wild-type McKrae or
dLAT2903R (P , 0.001) (Table 2). All 10 TGs
from rabbits infected with dLAT2903 were
positive according to this criterion, whereas
only 5 of 10 TGs from rabbits infected with
wild-type McKrae or dLAT2903R were posi-
tive (P 5 0.03) (Table 2). The sporadic low
levels of apoptosis detected in rabbit TGs in-
fected with wild-type McKrae were expected
because HSV-1 can induce apoptosis (13–16).
The results of these TUNEL assays suggest
that apoptosis was more likely, by a factor of 2
to 16, in rabbit TGs infected with the LAT2
mutant. Because HSV-1 can induce apoptosis
in infected tissue culture cells (13–16), we sus-
pect that the apoptotic neurons detected in TGs
by TUNEL were a direct result of the HSV-1
infection. However, because on day 7 (the time
of peak apoptosis) viral antigens can no longer
be detected in these TGs by immunofluorescent
staining (17), it is possible, but unlikely, that
some of the apoptosis may be due to a bystand-
er effect.
A newly devised method for detection of
apoptosis in tissue sections was used to confirm
the TUNEL results. TG sections obtained 7
days after infection were stained with an anti-
body to poly(ADP-ribose) polymerase (PARP)
(Anti-PARP p85 fragment pAb kit; Promega,
Madison, WI), as described by the manufactur-
er. Anti-PARP p85 detects caspase-3 cleavage
fragments of PARP, a hallmark of apoptosis
(18–20). Representative photomicrographs are
shown in Fig. 2. Extensive cleavage of PARP
was detected in five of six TGs from LAT2-
infected rabbits (.25% of neurons) but in none
of the four TGs from wild-type–infected rabbits
(P 5 0.048, Fisher exact test). All six LAT2
TGs contained detectable levels of cleaved
PARP staining, versus only one of four TGs
from rabbits infected with wild-type virus (P 5
0.03). To further confirm the similarity of the
TUNEL and anti-PARP p85 results, we pre-
pared seven pairs of sections, each pair from a
different TG. One section of each pair was
stained for TUNEL; the other section was
stained for PARP p85. A correlation was seen
between the percentage of positively stained
neurons on the TUNEL and anti-PARP p85
sections (R2 5 0.62, P 5 0.04; linear regres-
sion; P , 0.05 indicates that the R2 value was
unlikely to have occurred by chance). Confir-
mation of the TUNEL results by anti-PARP
p85 staining indicates that most of the TUNEL-
positive cells were due to apoptosis rather than
another mechanism of cell death or reaction
with viral DNA ends. Thus, LAT appeared to
decrease HSV-1–induced apoptosis in rabbit
Table 1. Apoptosis in rabbit TGs. Rabbits were infected with wild-type HSV-1 McKrae, dLAT2903 (LATÐ),
or dLAT2903R (LAT1) in both eyes (2 3 105 plaque-forming units per eye), as described (3). On the days
indicated after infection, two rabbits were killed per group. TGs were harvested and sectioned, and Þve
sections per TG (20 sections per group at each time point) were stained by the TUNEL assay that detects
DNA ends produced during apoptosis (Klenow-FragEL DNA fragmentation detection kit; Oncogene,
Cambridge, MA) as described by the manufacturer. Sections were read by light microscopy by two
individuals who had no knowledge of the groups and were considered positive for apoptosis if one or
more neurons were clearly positive. A TG was considered positive if one or more of its sections were
positive. For each TG, the sections used were obtained from different areas spanning the TG.
Criterion Day 3 Day 7 Day 10 Day 14
Sections with apoptotic neurons (%)
dLAT2903 5 70 10 5
dLAT2903R 0 0 20 5
McKrae 0 0 0 0
TGs with apoptotic neurons (%)
dLAT2903 0 100 25 25
dLAT2903R 0 25 25 25
McKrae 0 0 0 0
Fig. 1. Representative photomicro-
graphs of TUNEL-stained TG sec-
tions (upper and lower rows repre-
sent two different experiments).
Rabbits were infected, then killed 7
days after infection; TGs were har-
vested and sections were stained
for apoptosis by TUNEL, as de-
scribed in Table 1. (A) and (D), un-
infected; (B) and (E), McKrae-infect-
ed; (C) and (F), dLAT2903 (LAT2)Ð
infected. In (A) to (C), positive
staining is brown, counterstaining is
blue-green; magniÞcation, ;3150.
In (D) to (F), positive staining is
brown, counterstaining is green;
magniÞcation, ;3300. In (C), non-
neuronal cells (apparently inÞltrat-
ing immune cells), as well as neu-
rons, show strong staining for apo-
ptosis. In (F), brown dots in the
nucleus of large neurons indicate a
positive signal.
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TGs on day 7 after infection.
To more directly test the hypothesis that
LAT has an antiapoptotic activity, we used a
quantitative assay (21, 22) in which cells are
cotransfected with a b-galactosidase expression
plasmid (pCMV-b-gal) and an expression plas-
mid containing the gene of interest, in the pres-
ence of an inducer of apoptosis. If the gene of
interest (in this case, LAT ) reduces apoptosis,
the number of b-gal1 cells will be higher.
Apoptosis was induced by the sphingoid base
C6-ceramide (23–25), the mycotoxin fumonisin
B1 (FB1) (26, 27), or the anticancer drug eto-
poside. Primary human lung cells (IMR-90),
monkey kidney cells (CV-1), and murine neu-
roblastoma cells (neuro-2A cells) were used for
these studies.
An Apa I–Apa I LAT restriction fragment
(nucleotides 301 to 2659 of the 8.3-kb primary
LAT ) containing the entire stable 2-kb LAT
region from HSV-1 strain KOS (5) was inserted
into pBABE Puro, a mammalian expression
vector containing a retrovirus long terminal re-
peat (LTR), polyadenylate [Poly(A)] addition
signals, and the puromycin resistance gene reg-
ulated by the SV40 early promoter. The result-
ing plasmid (APALAT) was cotransfected into
the respective cells along with pCMV-b-gal.
IMR-90 and CV-1 cells were subsequently
treated with C6-ceramide or FB1 and neuro-2A
cells with etoposide. Relative to cultures co-
transfected with the empty pBABE Puro plas-
mid, the LAT-containing plasmid increased cell
survival in all cultures (as judged by the number
of b-gal1 cells) regardless of the agent used to
induce apoptosis (Fig. 3) (P , 0.0001;
ANOVA, Tukey posttest). Although the bacu-
lovirus antiapoptotic gene CpIAP (28) appeared
to inhibit apoptosis slightly more efficiently
than did LAT, the differences were not signifi-
cant (P . 0.05).
Ceramide-induced apoptosis is blocked by
activating protein kinase C (23, 25), whereas
blocking the tumor necrosis factor pathway
(TNF/FAS) inhibits FB1-induced apoptosis
(26, 29). Etoposide inhibits topoisomerase II,
thus leading to higher levels of DNA damage
and p53-dependent apoptosis (13, 14, 30).
The ability of LAT to block apoptosis induced
by each of these agents therefore suggests
that LAT interferes with a downstream effec-
tor of apoptosis that is common to many
apoptotic pathways. In addition, the ability of
the APALAT fragment to block apoptosis
mapped this function to within a region com-
prising only 28% of the primary LAT. The
ability of this region to promote efficient
establishment and subsequent reactivation
from latency (5) strengthens the likelihood
that LAT ’s antiapoptosis function plays an
important role in the latency reactivation cy-
cle. The antiapoptotic activity of LAT did not
appear to be HSV-1 strain specific, because
we saw this activity with strain McKrae–
derived viruses and strain KOS LAT.
Previous studies have reported that under
different conditions, herpes simplex virus can
induce or inhibit apoptosis (15, 31, 32). At
least two other viral genes, ICP27 and US3,
can protect certain cells against virus-induced
apoptosis in tissue culture (31, 32). Our re-
sults show that LAT can suppress apoptosis of
neurons (either in vivo or in vitro) and that
this function may explain the importance of
LAT in herpes simplex virus latency and re-
activation. Interestingly, we recently found
that the latency-related (LR) gene of bovine
herpes virus (BHV-1) also inhibits apoptosis
in transient transfection assays (33). BHV-1
and HSV-1 are only distantly related. The
Fig. 2. Photomicrographs of TG sec-
tions stained with anti-PARP p85
(magniÞcation, ;3300). Rabbits
were infected, then killed 7 days
after infection; TGs were harvested
and sections were stained for apo-
ptosis using the Anti-PARP p85
fragment pAb kit (Promega). Brown
dots in the nucleus and cytoplasm
of large neurons indicate positive
staining. Counterstaining is blue-
green. Representative photomicro-
graphs are shown. (A) Uninfected cells; (B) wild-type McKraeÐinfected cells; (C) dLAT2903 (LAT2)Ðinfected cells.
Table 2. Rabbits were infected and TGs harvested 7 days after infection. Five well-spaced sections were
stained for apoptosis and examined from each of 10 TGs per group (50 sections per group), except for
the uninfected control group, in which only 47 sections were examined.
Criterion dLAT2903 dLAT2903R McKrae Control
Sections with extensive apoptosis 33/50 (66%) 2/50 (4%) 2/50 (4%) 2/47 (4%)
TGs with extensive apoptosis 9/10 (90%) 1/10 (10%) 2/10 (20%) 1/10 (10%)
Sections with any apoptotic neurons 37/50 (74%) 11/50 (22%) 8/50 (16%) 17/47 (36%)
TGs with any apoptotic neurons 10/10 (100%) 5/10 (50%) 5/10 (50%) 10/10 (100%)
Fig. 3. In vitro inhibition of apoptosis by a LAT plasmid. IMR-90 cells (A), CV-1 cells (B), or neuro-2A cells
(C) were cotransfected with 1 mg of pCMV-b-gal (a b-galactosidase expression plasmid) and 5 mg of
APALAT (5). APALAT contains an Apa IÐApa I LAT restriction fragment (LAT nucleotides 301 to 2659)
inserted into pBABE Puro, a mammalian expression vector containing a retrovirus LTR, Poly(A) addition
signals, and the puromycin resistance gene regulated by the SV40 early promoter. Procedures for
calcium phosphate transfection and maintenance of cultures were as described (26). Twenty-four hours
after transfection, 10 mM C6-ceramide (Calbiochem, San Diego, CA) (23–25) or 25 mM fumonisin B1
(FB1) (26, 27) were added to IMR-90 and CV-1 cultures, and 15 mM etoposide (Sigma) was added to
neuro-2A cultures. After 48 hours, b-gal1 cells were identiÞed by staining the Þxed cells with Bluo-gal
(Gibco-BRL) for 24 hours; b-gal1 cells were counted in Þve Þelds. The number of b-gal1 cells in control
cultures treated with phosphate-buffered saline represents 100% survival. Data are averages from four
independent experiments. Cells were cotransfected with pCMV-b-gal and APALAT (APALAT ), pCMV-
b-gal and the empty expression plasmid instead of APALAT (pBABE Puro), or pCMV-b-gal and a plasmid
expressing the baculovirus CpIAP (inhibitor of apoptosis) gene instead of APALAT (CpIAP). Similar results
were obtained with a LAT restriction fragment not containing a Poly(A) signal.
R E P O R T S
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BHV-1 LR and the HSV-1 LAT have greatly
different sizes and little or no sequence sim-
ilarity. Although the BHV-1 LR antiapoptosis
function correlates with expression of an LR
protein (33), the LAT antiapoptosis function
may be mediated by the LAT RNA, because
LAT does not appear to encode a protein (34 ).
Our results suggest that LAT promotes neu-
ronal survival after HSV-1 infection by reducing
apoptosis. This hypothesis is supported by stud-
ies indicating that LAT2 mutants establish la-
tency less efficiently than does the wild type (5,
6, 35, 36) and that a mutant expressing an
altered LAT has increased neurovirulence (12).
In general, stress is associated with reactivation
and increased corticosteroid levels. Because cor-
ticosteroids induce apoptosis (37, 38), stress and
viral gene expression during reactivation may
induce apoptosis. Because LAT facilitates reac-
tivation (3, 39, 40), inhibition of apoptosis by
LAT would increase the probability that produc-
tive infection (i.e., productive reactivation from
latency) succeeds. Whether reactivation was
successful or not, LAT1 neurons may have a
better chance to survive and resume latency.
Thus, a LAT antiapoptosis function could allow
LAT to enhance reactivation by (i) enhancing the
establishment and maintenance of latency,
thereby providing more latently infected neu-
rons in which future reactivations could occur;
(ii) facilitating productive reactivation by pro-
tecting against apoptosis in neurons in which
reactivation occurs; and (iii) facilitating the re-
sumption of latency after a reactivation insult by
protecting neurons against apoptosis.
It is unlikely that LAT is the only factor
that promotes neuronal survival, because
terminally differentiated neurons must have
a well-devised mechanism to prevent pro-
grammed cell death. Furthermore, LAT may
have additional mechanisms by which it
enhances reactivation. Nonetheless, our re-
sults strongly suggest that suppressing ap-
optosis is an important mechanism by
which LAT enhances HSV-1 reactivation.
In addition, the ability of LAT to prevent
HSV-1–induced apoptosis may be impor-
tant in preventing the virus from causing
extensive neuronal damage and subsequent
neuronal disorders.
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Porphyrin and Phthalocyanine
Antiscrapie Compounds
Suzette A. Priola,* Anne Raines, Winslow S. Caughey
The transmissible spongiform encephalopathies (TSEs) are fatal, neurodegen-
erative diseases for which no effective treatments are available. The likelihood
that a bovine form of TSE has crossed species barriers and infected humans
underscores the urgent need to identify anti-TSE drugs. Certain cyclic tetra-
pyrroles (porphyrins and phthalocyanines) have recently been shown to inhibit
the in vitro formation of PrP-res, a protease-resistant protein critical for TSE
pathogenesis. We now report that treatment of TSE-infected animals with three
such compounds increased survival time from 50 to 300%. The significant
inhibition of TSE disease by structurally dissimilar tetrapyrroles identifies these
compounds as anti-TSE drugs.
The TSEs are a group of rare, fatal neurodegen-
erative diseases that include scrapie in sheep,
bovine spongiform encephalopathy (BSE) in
cattle, chronic wasting disease in deer and elk,
and Creutzfeldt-Jakob disease (CJD) in humans.
The onset of the BSE epidemic in cattle in Great
Britain raised concerns that humans could be at
risk through exposure to contaminated cattle
by-products. In 1996, a previously unknown
form of CJD (variant CJD or vCJD) was iden-
tified in young people in Great Britain (1). The
hypothesis that the most likely cause of vCJD
was exposure to BSE-contaminated materials
has since been supported by several different
studies (2). At present, over 40 cases of vCJD
have been confirmed, and there is some concern
that the number of cases could be on the rise (3).
Thus, with the potential exposure of millions of
people to BSE and the onset of vCJD, the need
for effective anti-TSE drugs has become acute.
A critical event in TSE pathogenesis is the
conversion of the normal protease-sensitive
host prion protein, PrP-sen, to a partially pro-
tease-resistant form (PrP-res) that is closely as-
sociated with disease pathogenesis. Studies
have shown that there is a close correlation
between compounds that inhibit PrP-res forma-
tion in vitro and compounds that inhibit TSE
disease (4). Therefore, PrP-res is an obvious
target for therapeutic intervention. The conver-
sion of PrP-sen to PrP-res involves changes in
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